REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS

被引：1

作者：

Addison, Daniel ^{[1
]}

Bonsu, Janice ^{[1
]}

Charles, Lawrence ^{[1
]}

Guha, Avirup ^{[1
]}

Baker, Brandee ^{[1
]}

Woyach, Jennifer ^{[1
]}

Awan, Farrukh ^{[1
]}

Rogers, Kerry ^{[1
]}

Lustberg, Maryam ^{[1
]}

Reinbolt, Raquel ^{[1
]}

Brammer, Jonathan ^{[1
]}

Miller, Eric ^{[1
]}

Jneid, Hani ^{[1
]}

Paskett, Electra ^{[1
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期

关键词：

D O I：

10.1016/S0735-1097(19)32485-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1331-429

引用

页码：1879 / 1879

页数：1

共 50 条

[21] Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
Molto Valiente, C.
Borrell, M.
Hwang, T.
Gich Saladich, I.
Barnadas, A.
Amir, E.
Kesselheim, A.
Tibau, A.
ANNALS OF ONCOLOGY, 2018, 29
[22] Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
Chen, Siliang
Li, Jiarui
JAMA NETWORK OPEN, 2021, 4 (03)
[23] Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs
Belknap, S. M.
Georgopoulos, C. H.
West, D. P.
Yarnold, P. R.
Kelly, W. N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 231 - 236
[24] ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials
Schwartz, Lisa M.
Woloshin, Steven
Zheng, Eugene
Tse, Tony
Zarin, Deborah A.
ANNALS OF INTERNAL MEDICINE, 2016, 165 (06) : 421 - +
[25] FDA to oversee reporting of clinical trials
Mark Ratner
Nature Biotechnology, 2012, 30 : 1163 - 1163
[26] FDA to oversee reporting of clinical trials
Ratner, Mark
NATURE BIOTECHNOLOGY, 2012, 30 (12) : 1163 - 1163
[27] Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies
Gajra, Ajeet
Zettler, Marjorie E.
Phillips, Eli G., Jr.
Feinberg, Bruce
BLOOD, 2020, 136
[28] Post-hoc power of clinical trials supporting anticancer drug approval by FDA.
Nadler, Michelle
Desnoyers, Alexandra
Saleh, Ramy
Amir, Eitan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023
Chen, Qi
Xu, Yang
Qu, Ruoxuan
Luo, Xingxian
Yang, Yue
DRUG DISCOVERY TODAY, 2024, 29 (09)
[30] Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
Maeda, H.
Kurokawa, T.
ANNALS OF ONCOLOGY, 2015, 26 (01) : 211 - 216

← 1 2 3 4 5 →